The company itself is the constraint: demand outrunning its own ability to take it on, and management is spending to rai
The model's full reasoning — Q3 2018 call → NOWe need to determine if management conveys that the company's own capability is the binding limit on growth, and that they are actively spending/building/hiring NOW to raise that limit, treating it as the central task. Let's review the transcript for relevant statements. Key points: - TIBSOVO launch: They have a sales team, but no mention of capacity constraints. They talk about increasing testing rates, physician awareness, etc. That's about demand generation. - They mention "we are opening new sites and enrolling patients" for mitapivat trials. That's clinical trial operations, not business capacity. - They mention "expanding our patient finding efforts" - that's about finding patients for trials, not about serving customers. - They mention "we have submitted the IND for AG-636" - that's R&D. - They mention "we are in the process of amending the study protocol" for AGILE - that's clinical trial design. - They mention "we are continuing to evaluate two molecules" - R&D. - They mention "we are on track to complete enrollment" in various trials - that's clinical development. None of this suggests that the company's own capability to serve, supply, or take on business is the binding limit. The company is a biotech with products in market (TIBSOVO, IDHIFA) and pipeline. The launch of TIBSOVO: they talk about "approximately 2,000 customer interactions" and "raising awareness" - that's about demand generation. They talk about "increasing testing rates" - that's about market development. They don't say they have more demand than they can handle. They mention "we are pleased with the uptake" and "we estimate over 100 unique prescribers" - that's about sales progress, not capacity constraints. They talk about "reimbursement" and "payer mix" - that's about market access. They talk about "we are not aware of any payer-related coverage issues" - that's about demand. They talk about "we expect the treatment duration to increase" - that's about patient mix. No mention of manufacturing capacity, supply constraints, or inability to meet demand. They mention "we ended the third quarter with what we believe is a reasonable level of TIBSOVO inventory to expect going forward" - that's about inventory, but not a constraint. They talk about "cost of sales" and "expense cost associated with the manufacturer" - that's accounting.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| BRBR | BellRing Brands, Inc. | Q4 2023 | 2023-11-21 | B+ |
| PRPH | ProPhase Labs, Inc. | Q1 2023 | 2023-05-11 | F |
| TSSI | TSS, Inc. | Q4 2022 | 2023-04-03 | D |
| TACT | TransAct Technologies Incorporated | Q4 2022 | 2023-03-08 | A |
| CHE | Chemed Corporation | Q3 2022 | 2022-11-01 | B+ |
| CRL | Charles River Laboratories International | Q2 2022 | 2022-08-03 | C |
| SYM | Symbotic Inc. | Q3 2022 | 2022-08-01 | B+ |
| JBHT | J.B. Hunt Transport Services, Inc. | Q2 2022 | 2022-07-19 | C+ |
| OGI | OrganiGram Holdings Inc. | Q3 2022 | 2022-07-14 | B+ |
| FLUX | Flux Power Holdings, Inc. | Q2 2022 | 2022-02-10 | D |
| GTES | Gates Industrial Corporation plc | Q4 2021 | 2022-02-07 | C+ |
| FORM | FormFactor, Inc. | Q4 2021 | 2022-02-02 | B |
| GFS | GLOBALFOUNDRIES Inc. | Q3 2021 | 2021-11-30 | A |
| HNRG | Hallador Energy Company | Q3 2021 | 2021-11-09 | C+ |
| FSS | Federal Signal Corporation | Q1 2018 | 2018-05-12 | A |
| AOSL | Alpha and Omega Semiconductor Limited | Q2 2018 | 2018-02-07 | B |
| LIND | Lindblad Expeditions Holdings, Inc. | Q2 2017 | 2017-08-06 | C |
| ZBH | Zimmer Biomet Holdings, Inc. | Q2 2017 | 2017-07-30 | F |
| GOGO | Gogo Inc. | Q1 2016 | 2016-05-06 | C+ |
ZBH · Q2 2017 → YESThe question is whether management conveys that the company's own ability to serve, supply, or take on business is the binding limit, and they're actively spending/building/hiring now to raise that li...YES The transcript shows management framing the Warsaw North Campus production delays and resulting back orders as the direct constraint on meeting existing customer demand and recapturing lost business, with steady market demand present but supply gating growth. They describe actively investing now in manufacturing remediation, quality enhancements, safety stock building, and sales force incentives and hires to restore full supply and return to offense, treating these as the central priority to expand capability and capture opportunities. This matches the criteria of internal capability as the binding limit and immediate action to raise it. The remediation is presented as urgent and ongoing rather than routine catch-up. The answer is YES.
FORM · Q4 2021 → YESThe question is whether management conveys that their own ability to serve/supply is the binding limit, and they're actively expanding now. YES The transcript shows management explicitly framing the company's internal limits—labor shortages in U.S. factories and extended lead times from sub-component delays—as the immediate ceiling on revenue growth, while simultaneously describing active, ongoing capital investments, facility expansions (Livermore), tool and labor additions, and supplier qualification efforts as the central priority to raise that ceiling and meet surging customer demand. This dual situation is presented as a present-tense reality driving the $850 million target path. The supply-chain component is acknowledged but subordinated to the claim that demand is outrunning current capability, and the build-out is treated as the key task ahead rather than routine maintenance.
FLUX · Q2 2022 → YESThe question is: Does management convey that the company's own ability to serve, supply, or take on business has become the binding limit on how big it can be right now — that real demand is pressing ...YES The transcript shows management explicitly framing the company's production capacity as the current binding limit: "We can’t build packs fast enough to keep up with the demand" and noting that supply-chain constraints (especially electronic components) are preventing them from serving the robust order flow and record backlog.